Loading
A second BRAF and MEK inhibitor pair, encorafenib plus binimetinib, shrank tumours in three quarters of untreated and nearly half of previously treated patients with BRAF V600E lung cancer, giving a better-tolerated alternative to dabrafenib-trametinib.
Phase 2 study of 98 patients with BRAF V600E-mutant metastatic non-small-cell lung cancer, 59 treatment-naive and 39 previously treated, given encorafenib plus binimetinib.
Objective response was 75 percent in treatment-naive and 46 percent in previously treated patients, with median duration of response not reached and 16.7 months respectively; pyrexia was less common than with dabrafenib-trametinib.
Encorafenib-binimetinib is approved for BRAF V600E lung cancer and offers a second targeted option, particularly for patients troubled by fever on dabrafenib-trametinib.
Shares Binimetinib, BRAF V600E-mutant non-small-cell lung cancer, Encorafenib.
Shares Binimetinib, Encorafenib.
Shares Binimetinib, Encorafenib.
Shares Binimetinib, Encorafenib.
Shares PHAROS, BRAF V600E-mutant non-small-cell lung cancer.
Shares Binimetinib, Encorafenib.
Shares Binimetinib, Encorafenib.
Shares Encorafenib, Journal of Clinical Oncology.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/